Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis

Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderl...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2021-08, Vol.57 (9), p.914
Main Authors: Sato, Shuzo, Matsumoto, Haruki, Temmoku, Jumpei, Fujita, Yuya, Matsuoka, Naoki, Yashiro-Furuya, Makiko, Asano, Tomoyuki, Suzuki, Eiji, Watanabe, Hiroshi, Kanno, Takashi, Migita, Kiyoshi
Format: Article
Language:English
Subjects:
abatacept
Biological products
Clinical medicine
DMARD
elderly
Infections
Medical prognosis
Patients
Remission (Medicine)
Retention
Rheumatoid arthritis
tacrolimus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Objectives: Treatment for elderly (aged ≥75 years) patients with rheumatoid arthritis (RA) is important because they usually have several complications and organ dysfunction and are more susceptible to drug-related adverse events. Abatacept (ABT) treatment is relatively safe in elderly RA patients; however, the real-world data of efficacy and long-term retention of ABT is sparse in such patients. This study aimed to investigate the clinical efficacy and long-term retention rates of ABT in elderly Japanese RA patients. Materials and Methods: This 10-year retrospective observational cohort study was performed in two centers in Fukushima, Japan. We reviewed the clinical features of elderly RA patients who received ABT and investigated the differences in retention rates with concomitant administration of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Results: The clinical characteristics of younger (
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina57090914